MP63-20 SUBCUTANEOUS FAT DISTRIBUTION IS A PROGNOSTIC BIOMARKER FOR MEN WITH CASTRATION-RESISTANT PROSTATE CANCER

Abstract

You have accessJournal of UrologyImaging/Radiology: Uroradiology IV1 Apr 2018MP63-20 SUBCUTANEOUS FAT DISTRIBUTION IS A PROGNOSTIC BIOMARKER FOR MEN WITH CASTRATION-RESISTANT PROSTATE CANCER Jong Soo Lee, Jee Soo Park, Yoon Soo Ha, Kwang Suk Lee, Hyun Kyu Ahn, Jee Soo Ha, Do Kyung Kim, Dong Hoon Lee, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, and Kyo Chul Koo Jong Soo LeeJong Soo Lee More articles by this author , Jee Soo ParkJee Soo Park More articles by this author , Yoon Soo HaYoon Soo Ha More articles by this author , Kwang Suk LeeKwang Suk Lee More articles by this author , Hyun Kyu AhnHyun Kyu Ahn More articles by this author , Jee Soo HaJee Soo Ha More articles by this author , Do Kyung KimDo Kyung Kim More articles by this author , Dong Hoon LeeDong Hoon Lee More articles by this author , Koon Ho RhaKoon Ho Rha More articles by this author , Sung Joon HongSung Joon Hong More articles by this author , Byung Ha ChungByung Ha Chung More articles by this author , and Kyo Chul KooKyo Chul Koo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2043AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The relationship between body fat distribution and survival remains unclear among patients with castration-resistant prostate cancer (CRPC) treated using docetaxel and androgen receptor-axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free survival (RFS) and cancer-specific survival (CSS) among patients with CRPC. METHODS This multi-center retrospective study evaluated data from 282 consecutive patients who were diagnosed with CRPC between September 2009 and March 2017. Subcutaneous fat index (SFI), visceral fat index (VFI), and skeletal muscle index (SMI) at the CRPC diagnosis were determined using computed tomography data (Figure: subcutaneous fat area [blue], visceral fat area [green], and skeletal muscle area [outlined in red] at the L3 level). Survival analyses were performed for SFI, VFI, and SMI dichotomized at 55.3 cm2/m2, 58 cm2/m2, and 52.4 cm2/m2, respectively. RESULTS At CRPC diagnosis, CSS was independently predicted by prostate-specific antigen levels, Gleason score ≥8, and a SFI <55.3 cm2/m2. During the median follow-up of 16.0 months, patients with a SFI of ≥55.3 cm2/m2 received more docetaxel cycles, compared to patients with a SFI of <55.3 cm2/m2. Compared to patients with a SFI of <55.3 cm2/m2, patients with a SFI of ≥55.3 cm2/m2 had better 1-year RFS (40.6% vs. 14.7%; p=0.002) and 2-year CSS (56.3% vs. 43.0%; p=0.045). The survival outcomes were not associated with VFI or SMI. CONCLUSIONS Patients with a SFI of ≥55.3 cm2/m2 at their CRPC diagnosis responded better to docetaxel chemotherapy, which may translate into higher RFS and CSS rates. As SFI can be easily determined using computed tomography, it may be a useful objective prognostic factor for discussing patients′ therapeutic options. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e849 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jong Soo Lee More articles by this author Jee Soo Park More articles by this author Yoon Soo Ha More articles by this author Kwang Suk Lee More articles by this author Hyun Kyu Ahn More articles by this author Jee Soo Ha More articles by this author Do Kyung Kim More articles by this author Dong Hoon Lee More articles by this author Koon Ho Rha More articles by this author Sung Joon Hong More articles by this author Byung Ha Chung More articles by this author Kyo Chul Koo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...